-
Location
-
San Francisco, CA
-
Summary
-
The estimated value of insider holdings of BVF PARTNERS L P/IL is at least $166M dollars as of 14 Oct 2025. BVF PARTNERS L P/IL is the 10%+ Owner of XOMA Royalty Corp and owns shares of XOMA Royalty Corp (XOMA) stock worth about $63.5M. BVF PARTNERS L P/IL is the Director, 10%+ Owner of MoonLake Immunotherapeutics and owns shares of MoonLake Immunotherapeutics (MLTX) stock worth about $52M. BVF PARTNERS L P/IL is the Director, Other* of Kymera Therapeutics, Inc. and owns shares of Kymera Therapeutics, Inc. (KYMR) stock worth about $17.8M. BVF PARTNERS L P/IL is the 10%+ Owner of Verastem, Inc. and owns shares of Verastem, Inc. (VSTM) stock worth about $10.9M. BVF PARTNERS L P/IL is the 10%+ Owner of Merus N.V. and owns shares of Merus N.V. (MRUS) stock worth about $6.47M. BVF PARTNERS L P/IL is the Director, Other* of Olema Pharmaceuticals, Inc. and owns shares of Olema Pharmaceuticals, Inc. (OLMA) stock worth about $3.72M. BVF PARTNERS L P/IL is the 10%+ Owner of Eledon Pharmaceuticals, Inc. and owns shares of Eledon Pharmaceuticals, Inc. (ELDN) stock worth about $3.63M. BVF PARTNERS L P/IL is the 10%+ Owner of Repare Therapeutics Inc. and owns shares of Repare Therapeutics Inc. (RPTX) stock worth about $2.96M. BVF PARTNERS L P/IL is the Other* of Third Harmonic Bio, Inc. and owns shares of Third Harmonic Bio, Inc. (THRD) stock worth about $2.53M. BVF PARTNERS L P/IL is the Other* of 4D Molecular Therapeutics, Inc. and owns shares of 4D Molecular Therapeutics, Inc. (FDMT) stock worth about $1.44M. BVF PARTNERS L P/IL is the 10%+ Owner of Cullinan Oncology, Inc. and owns shares of Cullinan Therapeutics, Inc. (CGEM) stock worth about $799K. BVF PARTNERS L P/IL is the Other* of PIERIS PHARMACEUTICALS, INC. and owns shares of PALVELLA THERAPEUTICS, INC. (PVLA) stock worth about $619K. BVF PARTNERS L P/IL is the 10%+ Owner of CRESCENT BIOPHARMA, INC. and owns shares of GLYCOMIMETICS INC (GLYC) stock worth about $15.6K.
-
Signature
-
BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President